期刊
JOURNAL OF IMMUNOLOGY
卷 205, 期 4, 页码 915-922出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.2000583
关键词
-
类别
资金
- National Institute of Allergy and Infectious Diseases (NIAID) [R21 AI139813, U01 AI141990, HHSN272201700060C, 75N93019C00062, 5T32CA009547, R01AI104739]
- NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]
- National Institutes of Health (NIH) [R01 AI127828]
- Defense Advanced Research Projects Agency [HR001117S0019]
- Collaborative Influenza Vaccine Innovation Centers [75N93019C00051]
- National Cancer Institute Cancer Center [P30 CA91842]
- National Center for Research Resources (an Institute for Clinical and Translational Science/Clinical and Translational Sciences Award) [UL1 TR000448]
- Helen Hay Whitney postdoctoral fellowship
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据